Disease Markers

Research Article

Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis

Table 4

The enriched pathways of top 4 modules from the protein-protein interaction network.


Module	Term	value	FDR	Genes

1	Cell cycle	7.17 − 13	5.94 − 10	CCNB1, CDK1, MAD2L1, CCNB2, BUB1, TTK, BUB1B, CHEK1, CDC20, MCM2, CCNA2
	Progesterone-mediated oocyte maturation	4.89 − 06	4.05 − 03	CCNB1, CDK1, MAD2L1, CCNB2, BUB1, CCNA2
	p53 signaling pathway	4.27 − 05	3.54 − 02	CCNB1, CDK1, CCNB2, RRM2, CHEK1
	Oocyte meiosis	2.85 − 04	0.235961	CDK1, MAD2L1, BUB1, AURKA, CDC20
	DNA replication	5.21 − 03	4.233590	POLE2, MCM2, RNASEH2A

2	Neuroactive ligand-receptorinteraction	4.44 − 11	4.86 − 08	OPRK1, GABBR1, NPY1R, GABBR2, ADORA1, S1PR3, GRM3, SSTR2, GRM2, GRM7, CNR1, S1PR5, ADRA2A
	Morphine addiction	2.16 − 08	2.36 − 05	ADCY1, ADCY5, GABBR1, GNB5, GABBR2, GNG3, ADORA1, GNG7
	Glutamatergic synapse	1.04 − 07	1.14 − 04	ADCY1, GRM3, GRM2, ADCY5, GRM7, GNB5, GNG3, GNG7
	GABAergic synapse	4.26 − 07	4.66 − 04	ADCY1, ADCY5, GABBR1, GNB5, GABBR2, GNG3, GNG7
	cAMP signaling pathway	4.42 − 06	4.84 − 03	ADCY1, SSTR2, NPY, ADCY5, GABBR1, GABBR2, NPY1R, ADORA1

3	Calcium signaling pathway	2.75 − 08	2.95 − 05	GRM5, PLCB4, CCKBR, CHRM3, CHRM1, PLCB1, GRM1, HTR2C, HTR2A, F2R
	Neuroactive ligand-receptorinteraction	9.29 − 08	9.95 − 05	GRM5, CCKBR, CHRM3, CHRM1, F2RL1, LPAR4, NTSR2, GRM1, HTR2C, HTR2A, F2R
	Gap junction	2.79 − 05	2.99 − 02	GRM5, PLCB4, PLCB1, GRM1, HTR2C, HTR2A
	Endocytosis	7.19 − 05	7.69 − 02	SH3GL3, DNM3, DAB2, DNAJC6, DNM1, SH3GL2, F2R, AMPH
	Inflammatory mediator regulation of TRP channels	6.88 − 04	0.734597	PLCB4, F2RL1, PLCB1, HTR2C, HTR2A

4	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	3.06 − 12	3.25 − 09	CACNA2D1, CACNG8, CACNB2, RYR2, CACNG3, CACNB3, CACNG2, CACNB4, CACNA2D3, CACNA1D
	Cardiac muscle contraction	5.12 − 12	5.43 − 09	CACNA2D1, CACNG8, CACNB2, RYR2, CACNG3, CACNB3, CACNG2, CACNB4, CACNA2D3, CACNA1D
	Hypertrophic cardiomyopathy (HCM)	7.38 − 12	7.82 − 09	CACNA2D1, CACNG8, CACNB2, RYR2, CACNG3, CACNB3, CACNG2, CACNB4, CACNA2D3, CACNA1D
	Dilated cardiomyopathy	1.47 − 11	1.56 − 08	CACNA2D1, CACNG8, CACNB2, RYR2, CACNG3, CACNB3, CACNG2, CACNB4, CACNA2D3, CACNA1D
	Oxytocin signaling pathway	1.77 − 10	1.88 − 07	CACNA2D1, CCND1, CACNG8, CACNB2, RYR2, CACNG3, CACNB3, CACNG2, CACNB4, CACNA2D3, CACNA1D

FDR: false discovery rate.